Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOURLIGHT-3: atirmociclib + letrozole versus CDK4/6 inhibitor + letrozole in first-line HR-positive/HER2-negative advanced breast cancer
CTR20250627Phase 3Active
- Sponsor
- Pfizer
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atirmociclib in breast cancer, sponsored by Pfizer. Started Mar 2025; status: active.
02
Drugs
atirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20250627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250627.